Study of an mRNA flu vaccine for adults
Part of Infections, Lungs & breathing clinical trials.
This trial is testing a new mRNA-based flu vaccine in healthy adults. It aims to see if the vaccine is safe and effective at preventing influenza.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are generally healthy and medically stable.
- You have not had the flu in the last 5 months.
- You have not received any flu vaccine (licensed or investigational) in the last 5 months.
- You have not taken antiviral flu medications like Tamiflu in the last 5 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new mRNA-based flu vaccines that may provide broader protection against different flu strains. Participants will receive the vaccine and be monitored for safety and their immune response.
This study tests a new flu vaccine to see how well it protects adults aged 18 to 64. If you join, you'll get the vaccine and have some check-ups to see how your body responds.
This study tests a new flu vaccine to see how well it helps the body fight off the flu. It is for generally healthy adults aged 18 to 59 who have not had the flu recently.
This study tests a new flu vaccine in adults aged 65 and older to see how well it prevents the flu. If you are generally healthy or manage chronic conditions well, you may be able to join.
This trial tests a new quadrivalent influenza (flu) vaccine in adults 18 and older. It aims to see if the vaccine is safe and helps protect against the flu. You may be able to join if you are generally healthy and have not had the flu or a flu shot recently.
This study tests an experimental flu vaccine in healthy children and teens to see if it is safe and how well it works. It may help protect against flu and is given as one or more shots.
Hear when a new Healthy Adults trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.